Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed Phase 2 Interventional Results available

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

NCT00402337
View directory record Official record
Conditions
Chronic Constipation
Interventions
linaclotide acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
60
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

NCT00129545
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
58
States / cities
Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04281472
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
efgartigimod PH20 SC in stage B, placebo in stage B
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

NCT02066636
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
127
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Late Hypothermia for Hypoxic-Ischemic Encephalopathy

NCT00614744
View directory record Official record
Conditions
Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic, Hypoxic-Ischemic Encephalopathy, Ischemic-Hypoxic Encephalopathy
Interventions
Hypothermia, Normothermic Control
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
6 Hours to 24 Hours
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

NCT00002944
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 9 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
179
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 31, 2026, 10:43 AM EDT
Recruiting Phase 3 Interventional

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

NCT06372964
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
56
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Terminated Phase 2 Interventional Results available

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00706914
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

NCT05412004
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Riverside, California • Brandon, Florida • Ocala, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 31, 2026, 10:43 AM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

NCT01711554
View directory record Official record
Conditions
Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions
Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Suspended Phase 1 Interventional

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

NCT05685602
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Gemcitabine Hydrochloride, Nab-paclitaxel
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
View directory record Official record
Conditions
Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
Interventions
cefixime, irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Paired Donation Consortium Paired Donation Program

NCT00374400
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Oct 31, 2026, 10:43 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome

NCT01425944
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Not listed
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
1 Month and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
7
States / cities
Baltimore, Maryland • Detroit, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Terminated Phase 3 Interventional Results available

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

NCT04458909
View directory record Official record
Conditions
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma, Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8
Interventions
Carboplatin, Cisplatin, Gemcitabine, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
322
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

NCT02442687
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily, Placebo
Drug
Lead sponsor
Manal Abdelmalek
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Dothan, Alabama • Chicago, Illinois • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Results available

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004
View directory record Official record
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

NCT00015652
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Aldesleukin, Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Results available

AMG 334 20160172 Pediatric Migraine PK Study.

NCT03499119
View directory record Official record
Conditions
Migraine
Interventions
AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT04754100
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
agenT-797
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Louisville, Kentucky • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 31, 2026, 10:43 AM EDT
Active, not recruiting Not applicable Interventional

AMPLATZER PFO Occluder Post Approval Study

NCT03309332
View directory record Official record
Conditions
Stroke, Patent Foramen Ovale
Interventions
AMPLATZER™ PFO Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

NCT00445887
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Levonorgestrel, Placebo
Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
30 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Orange, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 31, 2026, 10:43 AM EDT
Active, not recruiting Not applicable Interventional

3D Printed Models for Mandibular Fracture Repair

NCT05733221
View directory record Official record
Conditions
Mandible Fracture, Maxillofacial Trauma
Interventions
3D Printed Model
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 31, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Acceptance and Commitment Therapy (ACT) for OEF/OIF Veterans

NCT01253044
View directory record Official record
Conditions
Distress, Anxiety, Depression, Postconcussive Symptoms
Interventions
Acceptance and Commitment Therapy, Present Centered Therapy
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Augusta, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 31, 2026, 10:43 AM EDT